MedTrace Logo

Lidocaine Combined Dexmedetomidine for Obturator Nerve Block

NCT02066727 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-12-22

Study results available
· View outcomes & findings →

Summary

Hypothesis: Dexmedetomidine as an adjuvant of lidocaine can decrease the median effective concentration(EC50) of lidocaine for obturator nerve block during transurethral resection of bladder tumor

Conditions

  • Nerve Block

Interventions

DRUG

Dexmedetomidine

Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.

DRUG

Normal Saline

Normal Saline is administrated as an adjuvant of lidocaine.

Sponsors & Collaborators

  • Tianjin Medical University General Hospital

    collaborator OTHER

  • Guolin Wang

    lead OTHER

Principal Investigators

  • Guolin Wang, MD.PHD · Tainjin Medical University General Hospita

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-04-30
Completion
2014-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02066727 on ClinicalTrials.gov